OBJECTIVES: The objectives of this phase II trial were to assess the activity and tolerability of the combination of bevacizumab and erlotinib in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer. METHODS: This was a single arm, multicenter phase II trial with overall objective response as the primary endpoint. Eligible patients had two or fewer prior chemotherapy regimens for recurrent or refractory disease and no prior anti-VEGF or anti-EGFR agents. Bevacizumab, 15 mg/kg, was administered intravenously every 21 days and erlotinib, 150 mg orally, was given daily. RESULTS:Between July and October 2005, 13 patients were enrolled. There were two major objective responses, one complete response of 16+ month duration and one partial response of 11 month duration, for a response rate of 15% (95% CI 1.9% to 45.4%). Seven patients had a best response of stable disease. The most common grade 3 or 4 toxicities included anemia (n=1), nausea (n=2), vomiting (n=1), hypertension (n=1), and diarrhea (n=2). One patient with an ileostomy was removed from the study secondary to grade 3 diarrhea. Two patients had fatal gastrointestinal perforations. CONCLUSION: There was no strong suggestion that this combination was superior to single agent bevacizumab, and the rate of gastrointestinal perforation was of concern. The study was therefore stopped. Identification of risk factors for gastrointestinal perforation will be of importance for the use of bevacizumab in the treatment of ovarian cancer.
RCT Entities:
OBJECTIVES: The objectives of this phase II trial were to assess the activity and tolerability of the combination of bevacizumab and erlotinib in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer. METHODS: This was a single arm, multicenter phase II trial with overall objective response as the primary endpoint. Eligible patients had two or fewer prior chemotherapy regimens for recurrent or refractory disease and no prior anti-VEGF or anti-EGFR agents. Bevacizumab, 15 mg/kg, was administered intravenously every 21 days and erlotinib, 150 mg orally, was given daily. RESULTS: Between July and October 2005, 13 patients were enrolled. There were two major objective responses, one complete response of 16+ month duration and one partial response of 11 month duration, for a response rate of 15% (95% CI 1.9% to 45.4%). Seven patients had a best response of stable disease. The most common grade 3 or 4 toxicities included anemia (n=1), nausea (n=2), vomiting (n=1), hypertension (n=1), and diarrhea (n=2). One patient with an ileostomy was removed from the study secondary to grade 3 diarrhea. Two patients had fatal gastrointestinal perforations. CONCLUSION: There was no strong suggestion that this combination was superior to single agent bevacizumab, and the rate of gastrointestinal perforation was of concern. The study was therefore stopped. Identification of risk factors for gastrointestinal perforation will be of importance for the use of bevacizumab in the treatment of ovarian cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: J Fischer-Colbrie; A Witt; H Heinzl; P Speiser; K Czerwenka; P Sevelda; R Zeillinger Journal: Anticancer Res Date: 1997 Jan-Feb Impact factor: 2.480
Authors: James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg Journal: N Engl J Med Date: 2003-07-31 Impact factor: 91.245
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Richard T Penson; Don S Dizon; Stephen A Cannistra; Maria R Roche; Carolyn N Krasner; Suzanne T Berlin; Neil S Horowitz; Paul A Disilvestro; Ursula A Matulonis; Hang Lee; Modjulie A King; Susana M Campos Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: J M Bartlett; S P Langdon; B J Simpson; M Stewart; D Katsaros; P Sismondi; S Love; W N Scott; A R Williams; A M Lessells; K G Macleod; J F Smyth; W R Miller Journal: Br J Cancer Date: 1996-02 Impact factor: 7.640
Authors: Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts Journal: Clin Cancer Res Date: 2010-11-01 Impact factor: 12.531
Authors: Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills Journal: J Oncol Date: 2009-11-19 Impact factor: 4.375